Overview
BPC-157 Arginate is a salt form of BPC-157, the synthetic pentadecapeptide Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV). The peptide sequence is the same; the difference is the counter-ion, which is L-arginine rather than the acetate commonly supplied with synthetic peptides. BPC-157 corresponds to a partial sequence of body protection compound, a protein described in human gastric juice, and is also referred to in the literature as PL 147361.
Most published BPC 157 research describes the peptide without specifying a salt form, or used it as the acetate. Independent literature specific to the arginate salt is limited: we did not identify peer-reviewed studies of BPC-157 arginate itself, so the work summarised below concerns the BPC 157 peptide and should not be read as describing the arginate salt specifically. That work comes mainly from rodent models and cell culture1,2,3,4, with a 2025 systematic review identifying 36 eligible musculoskeletal studies, 35 of them preclinical7.
Mechanism of action
As described in the research literature
As described in the research literature, mechanistic work on the BPC 157 peptide has centred on angiogenic signalling. In a rat hind limb ischaemia model and in cultured human vascular endothelial cells, BPC 157 was associated with increased expression and internalisation of vascular endothelial growth factor receptor 2 (VEGFR2) and with time-dependent activation of the VEGFR2-Akt-eNOS pathway4.
In tendon fibroblasts isolated from rat Achilles tendon, the peptide was reported to increase cell migration and spreading and to raise phosphorylation of focal adhesion kinase (FAK) and paxillin, without directly altering proliferation in an MTT assay3. The counter-ion is not part of the peptide sequence, and no published study we identified has compared the arginate and acetate salts in these or other models.
Research areas
What published studies have examined
Salt form and what is known about it
In a peptide salt the counter-ion balances the charged side chains and termini; for BPC-157 Arginate it is L-arginine. Published studies of BPC 157 generally report the peptide without naming its salt, and no peer-reviewed study specific to the arginate salt was identified. A 2026 biopharmaceutical review noted that no pharmaceutical-grade BPC 157 formulation has been developed or validated and that permeability and excipient compatibility data are lacking6.
Sources [6]
Stability and pharmacokinetics of the peptide
The BPC 157 peptide is reported to be stable in human gastric juice1,6. A preclinical study in rats and beagle dogs reported an elimination half-life under 30 minutes, linear pharmacokinetics, and rapid metabolism of radiolabelled peptide into small fragments and amino acids, with excretion mainly in urine and bile5. These data describe the peptide; they were not generated with the arginate salt.
Sources [1] [5] [6]
Tendon and angiogenesis models
Studies in rats examined healing of the transected Achilles tendon using biomechanical, functional, microscopic and macroscopic measures, alongside in vitro work on cultured tendocytes2. Explant and fibroblast studies examined tendon outgrowth, cell survival under oxidative stress and migration3, and pro-angiogenic activity was examined in endothelial assays and a rat hind limb ischaemia model4.
Sources [2] [3] [4]
Evidence base and its limits
A 2025 systematic review screened 544 records on BPC 157 from an orthopaedic perspective and included 36 studies, of which 35 were preclinical, noting the absence of clinical safety data and concerns about unregulated manufacturing7. A 2026 review similarly described the pharmacokinetic profile as undercharacterised6. Neither review addresses the arginate salt specifically.
Sources [6] [7]
Specifications
- Sequence
- Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV)
- Salt form
- Arginate: the BPC-157 peptide with L-arginine as the counter-ion (in place of acetate)
- Molecular formula (peptide, free base)
- C62H98N16O22; the salt adds L-arginine (C6H14N4O2)
- Molecular weight (peptide, free base)
- 1419.5 g/mol
- CAS number (peptide, free base)
- 137525-51-0 (no separate PubChem record for the arginate salt)
- Form
- Units with a stated amount per unit, 100 to a resealable foil pouch
- Storage
- Store in a cool, dry place in the sealed pouch, away from direct light and moisture.
References
- 1
- 2
Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth.
Staresinic M, Sebecic B, Patrlj L, et al. Journal of Orthopaedic Research, 2003.
PubMed 14554208 ↗DOI 10.1016/S0736-0266(03)00110-4 ↗
- 3
- 4
- 5
Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.
He L, Feng D, Guo H, et al. Frontiers in Pharmacology, 2022.
PubMed 36588717 ↗DOI 10.3389/fphar.2022.1026182 ↗
- 6
BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers.
Mateescu DM, Gavrilescu DM, Constantinescu FE, et al. Pharmaceutics, 2026.
PubMed 42198317 ↗DOI 10.3390/pharmaceutics18050625 ↗
- 7